UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis

Biochemical and Biophysical Research Communications
Junrong WangYubo Hu

Abstract

Increasing evidence has demonstrated the involvement of dysregulated long non-coding RNAs (lncRNAs) in chemoresistance acting as potential oncogenes or tumor suppressors in various cancers. Nevertheless, the profound molecular mechanisms of lncRNAs in ovarian cancer (OC) chemoresistance is not well elucidated. The objective of this work was to investigate the role and molecular mechanisms of urothelial carcinoma associated 1 (UCA1) in paclitaxel (PTX) resistance in OC. Our results indicated that UCA1 was significantly up-regulated in PTX-resistant OC cells (SKOV3/PTX and HeyA-8/PTX) compared with their parental cells (SKOV3 and HeyA-8). Functionally, UCA1 knockdown sensitized SKOV3/PTX and HeyA-8/PTX cells to PTX through enhancing PTX-induced apoptosis. Mechanistically, UCA1 silencing induced PTX sensitivity of SKOV3/PTX and HeyA-8/PTX cells by de-repressing ABCB1 through sponging miR-129. Collectively, our study elaborated a novel UCA1/miR-129/ABCB1 regulatory axis underlying PTX resistance of OC cells, providing a potential therapeutic target for OC.

Citations

Jul 25, 2018·International Journal of Molecular Sciences·Alessandro La FerlitaCinzia Di Pietro
Jun 6, 2019·FEBS Letters·Wei XuanDandan Song
Jan 5, 2020·Journal of Molecular Neuroscience : MN·Sara MirzajaniMohammad Taheri
Apr 17, 2020·Klinicheskaia laboratornaia diagnostika·N E KushlinskiiE A Braga
Feb 11, 2020·Frontiers in Oncology·Cecilie AbildgaardSilvia R Rogatto
Dec 19, 2019·RNA Biology·Selin OnculGabriel Lopez-Berestein
Mar 4, 2020·Molecular Cancer·Xinyi ZhangYongguang Tao
Aug 4, 2020·Cancer Chemotherapy and Pharmacology·Jiahong JiangChun Yang
Jul 1, 2020·Cancer Metastasis Reviews·Yang PengYutaka Kondo
Nov 18, 2018·Cancers·Bernadette NeveIsabelle Van Seuningen
Nov 27, 2020·International Journal of Molecular Sciences·Eleonora A BragaNikolay E Kushlinskii
Jan 12, 2021·Cancer Letters·Vipul BhardwajVijay Pandey
Dec 29, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Soudeh Ghafouri-FardMohammad Taheri
Jan 28, 2021·International Journal of Molecular Sciences·Nicholas CardilloJesus Gonzalez-Bosquet
Dec 24, 2019·Acta Pharmaceutica Sinica. B·Yuhua LiHuichang Bi
Dec 23, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Julia Gallego-JaraTeresa de Diego Puente
Mar 9, 2020·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Wenxiao JiangXueqiong Zhu
Nov 19, 2020·Seminars in Cancer Biology·Wangkai XieZhi-Wei Wang
Dec 31, 2019·Gynecologic Oncology·Anaïs WambeckeMatthieu Meryet-Figuiere
Sep 26, 2020·Biochemical Pharmacology·Ying ZhouLushan Yu
May 18, 2021·Frontiers in Cell and Developmental Biology·Toshihiko TakeiwaSatoshi Inoue
Jul 3, 2021·International Journal of Molecular Sciences·Jorge Melendez-Zajgla, Vilma Maldonado
Aug 3, 2021·Experimental and Therapeutic Medicine·Bingpeng DengYong Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.